LITTLE FALLS, NJ – January 8, 2007 - Sentrx, a leading provider of drug safety services, announced today that in 2006 it doubled the number of biopharmaceutical companies it serves. Sentrx also renewed contracts with several long-term clients and expanded the scope of services with others.

Sentrx began offering adverse event case processing in 1999. Since then, its reputation for providing reliable clinical trial safety monitoring and post-marketing safety surveillance has grown steadily.

A testimony to the high level of client satisfaction Sentrx delivers is the fact that four clients renewed their contracts in 2006 for additional three-year terms. Sentrx has provided clinical trial safety, post-marketing safety surveillance, and safety system hosting to one of these companies for more than six years. During this time, data migration and MedDRA version upgrade projects were performed as needed, and electronic submissions capability was added this year. Other contract renewals represent companies that have been clients for up to four years.

"The demand for Sentrx drug safety services has never been stronger, nor has our ability to meet the demand," said Joseph Albano, Chief Executive Officer of Sentrx. "We appreciate the confidence our new and long-term clients have placed in us, and in 2007 we will continue to earn their trust every day."

Highlights of 2006 for Sentrx and its clients include:

• Eleven new multi-year contracts gained
• Four multi-year contract renewals signed
• Safety system hosting platform upgraded to SunGard’s "always-on" facility
• Electronic submissions capability to FDA and EMEA implemented for clients
• Literature search capability expanded for clients through Thomson Scientific partnership
• MedDRA version management automated for hosted clients

About Sentrx
Sentrx is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to help pharmaceutical, biotechnology, medical device, and consumer health companies document the safety profile of their products during clinical development and postapproval, enabling them to minimize risks and maximize benefits. Through its multilingual Safety Response Center, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please visit their website at www.sentrx.com, or call 1-888-399-8032, extension 261.